Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA Stock Report

Market Cap: US$8.2m

Processa Pharmaceuticals Management

Management criteria checks 3/4

Processa Pharmaceuticals' CEO is George Ng, appointed in Aug 2023, has a tenure of 2.75 years. total yearly compensation is $673.30K, comprised of 59.4% salary and 40.6% bonuses, including company stock and options. directly owns 0.39% of the company’s shares, worth $31.62K. The average tenure of the management team and the board of directors is 5.7 years and 6.2 years respectively.

Key information

George Ng

Chief executive officer

US$673.3k

Total compensation

CEO salary percentage59.41%
CEO tenure2.8yrs
CEO ownership0.4%
Management average tenure5.7yrs
Board average tenure6.2yrs

Recent management updates

Recent updates

Analysis Article • Dec 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 20

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Seeking Alpha • Aug 12

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Processa Pharmaceuticals press release (NASDAQ:PCSA): Q2 GAAP EPS of $0.53 beats by $0.73. Company cash balance on June 30, 2022, was $12.1 million,
Analysis Article • Jul 07

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 20

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Aug 26

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Mar 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

The big shareholder groups in Processa Pharmaceuticals, Inc. ( NASDAQ:PCSA ) have power over the company. Institutions...
Analysis Article • Jan 20

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

CEO Compensation Analysis

How has George Ng's remuneration changed compared to Processa Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$14m

Dec 31 2025US$673kUS$400k

-US$14m

Sep 30 2025n/an/a

-US$13m

Jun 30 2025n/an/a

-US$13m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$521kUS$400k

-US$12m

Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$712kUS$159k

-US$11m

Compensation vs Market: George's total compensation ($USD673.30K) is about average for companies of similar size in the US market ($USD627.70K).

Compensation vs Earnings: George's compensation has increased whilst the company is unprofitable.

CEO

George Ng (51 yo)

2.8yrs
Tenure
US$673,303
Compensation

Mr. George K. Ng, Esq. JD, serves as CEO of Processa Pharmaceuticals, Inc. since August 08, 2023 and serves as its Director since August 08, 2023 and served as its Director since August 08 2023 until 2024....

Leadership Team

NamePositionTenureCompensationOwnership
George Ng
CEO & Director2.8yrsUS$673.30k0.39%
$ 31.6k
Sian Bigora
Co-Founder and Chief Development & Regulatory Officerno dataUS$495.10k0.28%
$ 23.0k
Russell Skibsted
Chief Financial Officer1.8yrsUS$652.72k0.24%
$ 19.9k
David Young
Co-Founder9.3yrsUS$305.42k0.54%
$ 43.7k
Patrick Lin
Co-Founder9.3yrsUS$1.04m0.30%
$ 24.5k
Wendy Guy
Co-Founder8.6yrsUS$1.02m0.24%
$ 19.8k
Steven Cha
Senior Vice President of Clinical Research2.1yrsno datano data
5.7yrs
Average Tenure
63yo
Average Age

Experienced Management: PCSA's management team is seasoned and experienced (5.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
George Ng
CEO & Director2.8yrsUS$673.30k0.39%
$ 31.6k
David Young
Co-Founder8.6yrsUS$305.42k0.54%
$ 43.7k
James Neal
Independent Director3.8yrsUS$100.00k0.031%
$ 2.5k
John Devane
Member of Medical & Scientific Advisory Board6.2yrsno datano data
Justin Yorke
Independent Chairman of Board8.8yrsUS$100.00k0.024%
$ 2.0k
James Shipley
Member of Medical & Scientific Advisory Board6.2yrsno datano data
Khoso Baluch
Independent Director3.8yrsUS$100.00k0.087%
$ 7.1k
Geraldine Pannu
Independent Director6.3yrsUS$100.00k0.082%
$ 6.7k
6.2yrs
Average Tenure
62.5yo
Average Age

Experienced Board: PCSA's board of directors are considered experienced (6.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 07:34
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Processa Pharmaceuticals, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robin Garner KalleyCraig-Hallum Capital Group LLC
Raghuram SelvarajuH.C. Wainwright & Co.
Nazibur RahmanMaxim Group